Skip to main content

The Skimune® platform (Skimune®Cosm; Skimune®Chem; Skimune®Mab) are unique non-artificial human in vitro skin tests

The Skimune® platform predicts hypersensitivity responses to pharmaceuticals including small molecule drugs and monoclonal antibodies, chemicals and cosmetics

Skimune® provides a pre-clinical predictive readout of skin damage which correlates with screening assays ie. cytokine release and T cell proliferation

Skimune®Mab is the only commercially available test for predicting adverse immune reactions to monoclonal antibodies, biobetters, biosimilars and antibody drug conjugates

The Skimune® platform tests are also used in dose response and efficacy studies for immunomodulatory drugs prior to Phase One clinical trials

The Skimune® 3D high throughput screening for the detection of sensitisation and toxicity to drugs, chemicals and cosmetics

Meet the team

Professor Anne Dickinson

Founder and Director

Anne’s research at Newcastle University led to the founding of Alcyomics in 2007. Due to her expertise in immunobiology she has developed human skin based in vitro assays for predicting clinical responses prior to clinical trial.

Dr Shaheda Ahmed

Scientific Manager

Shaheda’s expertise includes cell and molecular biology and human skin explant assay technology.

Dr Asif Tulah

BD Manager

Asif’s expertise includes cell biology, dermatology, and in vitro 3D assay technology.

  • This form collects your name and email so what we can add your to our newsletter list and send you relevant updates via email. Read our privacy policy for details on how we manage your data.